Search Results - "Andrius Zucenka"
-
1
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation
Published in Bone marrow transplantation (Basingstoke) (01-11-2021)“…We retrospectively compared the outcomes of 20 patients receiving Venetoclax + low-dose Cytarabine + Actinomycin D (ACTIVE) with 29 patients receiving FLAG-Ida…”
Get full text
Journal Article -
2
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
Published in Annals of hematology (01-05-2021)“…We retrospectively collected clinical data on 31 relapsed or refractory acute myeloid leukemia (R/R AML) patients who were treated with outpatient glasdegib…”
Get full text
Journal Article -
3
The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
Published in Journal of fungi (Basel) (23-04-2022)“…Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell…”
Get full text
Journal Article -
4
Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan
Published in International journal of cardiology. Heart & vasculature (01-02-2021)“…To assess cardiac safety in COVID-19 patients treated with the combination of Hydroxychloroquine and Azithromycin using arrhythmia risk management plan. We…”
Get full text
Journal Article -
5
Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia
Published in British journal of haematology (01-04-2024)“…We have conducted a retrospective, single-centre analysis of 20 patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (FLT3m AML) who…”
Get full text
Journal Article -
6
A Case of Successful Allogeneic Hematopoietic Stem Cell Transplantation in a Severely Underweight Patient with Aplastic Anemia
Published in Case reports in hematology (04-03-2024)“…Allogeneic hematopoietic stem cell transplantation (alloHSTC) is considered definitive and the most effective treatment for young patients diagnosed with…”
Get full text
Journal Article -
7
Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement
Published in Pathology oncology research (09-01-2023)“…Extranodal natural killer/T-cell lymphoma (ENKL) is a rare subtype of mature T and natural killer cell lymphomas associated with Epstein-Barr virus. A…”
Get full text
Journal Article -
8
Oxidative phosphorylation inhibition induces anticancerous changes in therapy‐resistant–acute myeloid leukemia patient cells
Published in Molecular carcinogenesis (01-11-2019)“…Treatment of acute myeloid leukemia (AML) is still a challenge because of common relapses or resistance to treatment. Therefore, the development of new…”
Get full text
Journal Article -
9
Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
Published in Case reports in hematology (15-10-2020)“…Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic…”
Get full text
Journal Article -
10
Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies
Published in Bone marrow transplantation (Basingstoke) (01-06-2022)Get full text
Journal Article -
11
Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission
Published in Frontiers in genetics (12-04-2022)“…Acute myeloid leukemia (AML) is an aggressive, heterogeneous group of malignancies with different clinical behaviors and different responses to therapy. For…”
Get full text
Journal Article -
12
P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA
Published in HemaSphere (08-08-2023)Get full text
Journal Article -
13
Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study
Published in Medicina (Kaunas, Lithuania) (30-11-2021)“…: Oncohematological patients have a high risk of mortality when they need treatment in an intensive care unit (ICU). The aim of our study is to analyze the…”
Get full text
Journal Article -
14
-
15
Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients
Published in Blood (02-11-2023)“…Background Allogeneic stem cell transplantation (alloSCT) is the cornerstone therapy for myelodysplastic syndromes with increased blasts-2 (MDS-IB2). However,…”
Get full text
Journal Article -
16
Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting
Published in Blood (23-11-2021)“…Background Venetoclax based therapies have produced varying results in the relapsed or refractory acute myeloid leukemia (R/R AML) setting. Highest response…”
Get full text
Journal Article -
17
Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant
Published in Blood (02-11-2023)“…Background: The potent and selective oral menin-histone-lysine N-methyltransferase 2A (KMT2A) inhibitor revumenib (SNDX-5613) induced complete remissions with…”
Get full text
Journal Article -
18
HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
Published in Journal of oncology (2019)“…Acute promyelocytic leukemia (APL) is characterized by PML-RARA translocation, which causes the blockage of promyelocyte differentiation. Conventional…”
Get full text
Journal Article -
19
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
Published in The Lancet. Haematology (01-09-2023)“…The existence of two acute myeloid leukaemia classification systems—one put forth by WHO and one by the International Consensus Classification in 2022—is…”
Get full text
Journal Article -
20
P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE
Published in HemaSphere (08-08-2023)Get full text
Journal Article